NBIO News and Press, Nascent Biotech From 06/07/23

NORTH PALM BEACH, FL / ACCESSWIRE / June 7, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space presented their Phase I Clinical Data at the American ...

NORTH PALM BEACH, FL / ACCESSWIRE / May 26, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company and China based BioR...

2023-05-10 04:59:28 ET Nascent Biotech Inc. (OTCMKTS:NBIO) presents an interesting object of study for speculators and long-term investors with an interest in unearthing potentially powerful growth stocks that […] For further details see: Why Biotech Sleeper NBIO Could be Nearing...

NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company has been selected for...

NORTH PALM BEACH, FL / ACCESSWIRE / April 18, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in the brain cancer space, announced today that the Protocol for the Phase 2 clinical trials ...

2023-03-21 07:55:06 ET Monoclonal antibodies (mAbs) are laboratory-produced molecules that can mimic the immune system’s ability to target and destroy cancer cells. These antibodies are designed to bind […] For further details see: NBIO Vies for Phase II Kick-Off After 8yr...

NORTH PALM BEACH, FL / ACCESSWIRE / February 28, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in the brain cancer space, announced today that the Company has completed and closed its P...

2023 has been surprising for most market participants. Sentiment was in the toilet to close out 2022. And the first two weeks of this year […] For further details see: NBIO Flying Under the Radar Ahead of Potential Major Catalyst

NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period of t...

Markets are starting to perk up in 2023 after a long and difficult bear market year in 2022. Investors eager to put capital back to […] For further details see: NBIO Fits Profile for Strategy Targeting Early Stage Biotech